US EditionPublished • loading... • Updated
Thrombolex Secures Financing for Commercialization of Bashir Catheters for Pulmonary Embolism Treatment
Summary by Endovascular Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Endovascular TodayReposted by 
Cardiac Interventions Today
Cardiac Interventions TodayThrombolex Secures Financing for Commercialization of Bashir Catheters for Pulmonary Embolism Treatment
March 17, 2026—Thrombolex, Inc., a commercial-stage developer of a differentiated pharmacomechanical lysis platform for the treatment of pulmonary embolism and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed and supported by current investors and cofounders. According to the company, the financing strengthens its capital position as it expands its United States commercial infrastruct…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
